Echinacea spp. are popularly used as an herbal medicine or food supplement for enhancing the immune system. This study shows that plant extracts from root [R] and stem plus leaf [S+L] tissues of E. purpurea exhibit opposite (enhancing vs inhibitory) modulatory effects on the expression of the CD83 marker in human dendritic cells (DCs), which are known as professional antigen-presenting cells. We developed a function-targeted DNA microarray system to characterize the effects of phytocompounds on human DCs. Down-regulation of mRNA expression of specific chemokines (e.g., CCL3 and CCL8) and their receptors (e.g., CCR1 and CCR9) was observed in [S+L]-treated DCs. Other chemokines and regulatory molecules (e.g., CCL4 and CCL2) involved in the c-Jun pathway were found to be up-regulated in [R]-treated DCs. This study, for the first time, demonstrates that E. purpurea extracts can modulate DC differentiation and expression of specific immune-related genes in DCs.
Echinacea, also known as purple coneflower, has become a top-selling medicinal herb and food supplement in Europe and the United States [1] . Three major species, E. purpurea, E. angustifolia, and E. pallida, have been studied for their possible pharmacological and immunological effects [2] [3] [4] . In previous studies, E. purpurea was reported to increase chemotoxicity in neutrophils, bactericidal activity against Staphylococcus [5] , and production of TNFα, interleukin (IL)-10, IL-6, and IL-1β in macrophages [6] . However, the specificity and mechanisms of the actions of phytocompounds from Echinacea plants on defined human immune systems remained to be addressed, mainly because of lack of systematic studies using advanced cell and gene-based technology [7] .
Dendritic cells (DCs) are professional antigen-presenting cells that play a key role in mediating activities of various immune systems, including primary innate immune responses and T-cell-mediated immune responses [8] . DCs have been actively investigated recently for use as effectors or adjuvants in cancer vaccines or cell-based immunotherapy [9] . Investigations into the specific effects of phytocompounds or herbal extracts on DCs would be beneficial for translational medicine research and may provide scientific support for the immunemodulatory activities of traditionally used or newly identified medicinal herbs.
Functional genomic approaches have become a new strategy for biological studies, generally by use of subgenomic (e.g., ≈1/2 of a human genome size, with ∼10,000 genes) DNA microarray systems. Such DNA microarray technologies can be used to monitor unclear gene interactions in a global way [10] [11] [12] . Previously, several studies utilized DNA microarrays to analyze differential gene expression in DCs, to survey the cascade actions of transcriptional induction [13] and to profile changes in gene expression during DC maturation [14] . In this study, we developed an oligonucleotide-based array system to evaluate the differential gene expression patterns in human immature DCs Genomics 88 (2006) 801 -808 www.elsevier.com/locate/ygeno (imDCs) in response to the immunomodulatory activities of phytocompounds from E. purpurea extracts. Herbal medicine has been empirically used for treating diseases or improving the immune system for ages. However, until recently, little or no systematic evidence-based research into a series of anecdotally claimed effects was performed, and as a result, clear demonstrations of pharmacological efficacy were often not available. Because E. purpurea is known for its potential immunostimulatory activity, we studied here the effect of various tissue extracts of E. purpurea on specific cellbiological activities of human monocyte-derived DCs. We evaluated the bioactivity of Echinacea extracts on various cell surface markers of human DCs, including CD83, CD32, and HLA-DR, known to be involved in specific cellular and/or physiological functions of DCs. Furthermore, we also investigated possible modulatory effects of Echinacea extracts on the gene transcription level in DCs with the use of a home-designed small-scale gene chip of 225 immune-function-associated or reference genes. Various genes in the DNA miniarray included specific chemokines, chemokine receptors, antigen processing molecules, cytokines, CD markers involved in DC maturation, molecules involved in immune cell interaction as well as signaling pathways and apoptosis of DCs, and a group of known housekeeping genes. Our results demonstrated that this small-scale, function-targeted DNA microarray system can be employed to evaluate the differential gene expression patterns of DCs in response to treatment with medicinal plant extracts.
Results

Modulatory effects of Echinacea extracts on CD markers of DCs
Highly purified primary human monocyte-derived dendritic cells were routinely obtained for analysis of bioactivity of Echinacea extracts. The addition of cytokines, including GM-CSF and IL-4, to monocytes in culture can effectively result in their differentiation into imDCs as indicated by the expression of CD32 (a representative CD marker for imDCs) and the low expression level of CD14 (a specific cell-surface marker of monocytes) (Fig. 1 , as seen from the 0 dose of extract treatments) [14] . Plant extracts of E. purpurea were tested for their effects on cultured primary imDCs. Figs. 1A-1D show that the expression levels of CD14 marker in Echinacea extracttreated imDCs were found to be similar to those of control cells (not treated). However, dendritic cells treated for 24 h with Statistical analyses between vehicle control (0 dosage) and extract treatment (1-500 μg/ml) were performed using Student's t test. Significant inhibition is indicated: *p < 0.05, **p < 0.005, and ***p < 0.001. We also evaluated the effects of E. purpurea extracts on the expression of CD83, a key marker for DC maturation. As seen in Fig. 2A To evaluate whether the effects on the expression of CD markers in DCs could have resulted from a cytotoxic effect of the extracts, we used a 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to examine the viability of test DCs. At concentrations between 1 and 100 μg/ml, all extracts, except for [W], were not cytotoxic (Fig. 3) . However, at the highest dose (500 μg/ml), cytotoxicity was detected with [W] 
Differential gene expression in DCs as a response to treatment with Echinacea extract
We used homemade mini-DNA chips, containing 225 genes with quartet spot-formatted sets of known human immunerelated genes, to collect genomic information on the possible mechanism(s) of E. purpurea extract-modulated DC activities.
[R] and [S+L] extracts that exhibited opposite (enhanced vs suppressed) modulatory effects on CD83 expression in imDCs were used. Since a high concentration of Echinacea extracts (e.g., [S+L] extract at 500 μg/ml) could result in partially cytotoxic effects in DCs, we used doses of 100 μg/ml. Results from three independent experiments showed that normalized signals at 4 and 16 h post-treatment with [R] or [S+L] extracts related well and were reproducible. Along with statistical analysis of the annotation of specific genes and gene clusters, a summary of our key findings on the differentially expressed genes in these DCs is shown in Tables 1 and 2 . For up-regulated and down-regulated genes, we considered only those with at least a 2-fold change in the level of RNA transcript expression in three independent experiments. Differences in expression were calculated by dividing the signal intensity values of genes from [R]-or [S+L]-treated cells by intensity values of genes from vehicle (control)-treated cells. Among the 225 genes, only 13 genes were up-regulated 2-to 4-fold in [R]-treated imDCs (for both 4-and 16-h treatments), whereas no genes were downregulated in comparison to vehicle-treated cells (Table 1) . In contrast, only down-regulated gene expression was observed in [S+L]-treated imDCs. Twenty-eight genes were found to be suppressed between 2.1-to 5.9-fold in [S+L]-treated imDCs in comparison to cells treated with vehicle (control) only (Table 2) .
Metabolite profiling of phytocompounds from tissue extracts of E. purpurea
To ensure the consistency of the Echinacea extract test in this study, metabolite profiling of the total 70% ethanolic control. Statistical analyses between vehicle control (0 dosage) and extract treatment (1-500 μg/ml) were performed using Student's t test. Significant difference is indicated: *p < 0.05, **p < 0.005, and ***p < 0.001. extracts of flowers, shoot plus leaf, and root extracts of E. purpurea was analyzed with high-performance liquid chromatography (HPLC) and liquid chromatography/mass spectrometry (LC/MS) (Fig. 4) . Compounds 1 and 2 were identified as cichoric acid and rutin, respectively, by comparing their retention time and MS data to those of their respective authenticated standards. Quantification of compounds 1 and 2, used as index compounds in this study, in the chromatogram of a known concentration of the plant extracts was calculated from a standard calibration curve of the individual index compounds. The relative content of cichoric acid and rutin was 11.4 and 15.0%, 3.7 and 11.2%, and 3.4 and 9.4% (in dry weight) for [F] , [S+L] , and [R] extracts, respectively. The metabolite profiles and the relative contents of the index compounds were routinely used for quality control of specific test tissue extracts.
Discussion
E. purpurea is one of the Echinacea species widely used currently for nutraceutical or pharmaceutical purposes. Various tissue extracts of this traditional medicinal plant have been reported to have immunostimulatory activity on a number of human immune cells, such as macrophages and peripheral blood mononuclear cells [4, 15] . DCs are known to play a key role in the interface between the innate and the acquired immune systems. In response to exogenous stimuli (e.g., LPS) as well as endogenous signals, DCs undergo a programmed maturation to become efficient, antigen-presenting cells. We hence investigated whether specific and important cellular and molecular activities in human DCs could be affected by treatment with plant extracts from E. purpurea. Our findings are the first to demonstrate the effects of E. purpurea extracts on differentiation and modulation of human DCs at the cellular and subgenomic levels. Results from flow cytometry studies suggest that the level of CD83 marker expression, a representative marker of DC maturation, can be significantly enhanced by treatment with [F] or [R] extracts but that CD83 levels can be The promoting activity of [R] extract of E. purpurea on DC maturation was similar to the effect of LPS on DCs (Fig. 2) , as verified by the expression of CD83 on flow cytometry. We further examined the gene expression profile of [R] extract-treated DCs using a homemade mini-DNA microarray. In previous studies [16, 17] , the expression of the chemokines CCL2 and CCL3 and the nonclassical major histocompatibility complex (MHC) class I-like molecule CD1A was up-regulated in LPS-simulated DCs. Here we found that the expression of these three genes was effectively up-regulated upon treatment with [R] extract of E. purpurea (Table 1) . These results suggest that certain phytocompounds in the [R] extract may play a role similar to LPS in promoting the maturation of DCs. The [S+L]-treated imDCs were further used in mini-DNA microarray assays to characterize whether specific gene transcriptional activities could be associated with the suppressive effect of [S+L] extract on DC maturation. Results in Table 2 show that the chemokines CCL3 and CCL8 and the nonclassical MHC class I-like molecule CD1A were down-regulated in [S+L]-treated DCs, concomitant with the inhibitory effect conferred by this tissue extract on CD83 expression. IGF1R, an insulin-like growth factor 1 receptor, was also up-and down-regulated with [R] and [S+L] treatment, respectively. These data indicate that CCL3, CD1A, and IGF1R may be highly regulated or coordinated with the activity of DC maturation responsive to E. purpurea extracts.
c-JUN, an important transcription factor, previously reported to be involved in specific cytokine production and the regulation of DC maturation [18] , was up-regulated at the transcriptional level in [R]-treated DCs. A number of genes involved in immune cell activation or functions, such as CCL4, IL7R, NFATC2, TBX21, PSCDBP, ITGAE, and ICAM1, were up-regulated in DCs by treatment with [R] extract (Table 1 ). The expression of the chemokine receptors CCR1 and CCR9 and that of their corresponding chemokines CCL8 and CCL3 were highly correlated in [S+L]-treated DCs in that they were all down-regulated (Table 2) . Gene products involved in immune cell interactions or functions, such as CD34 and ITGB1, were also down-regulated in [S+L]-treated DCs. These results imply that the [S+L] extract of E. purpurea may be able to attenuate the adhesion, chemotaxis, or activation functions of specific immune cell types such as DCs. Interestingly, transcription factor STAT1, tumor necrosis factor superfamily 6 (FASLG), β2-microglobulin (B2M), elongation factor WNT1, and transcription factor ETV5 were all significantly down-regulated (0.17-to 0.27-fold the expression of the vehicle-treated DCs) in DCs treated with the [S+L] extract. These groups of immunomodulatory genes thus provide candidates for future studies of medicinal phytocompounds on human DCs.
Cichoric acid has been reported [15] to be a major compound present in E. purpurea extract. Fig. 4 
shows the LC/MS results of analysis of the phytocompound profiles of [F], [S+L], and [R]
extracts of E. purpurea. The presence of cichoric acid as a major constituent of test samples is consistent with previous findings. However, DCs treated with cichoric acid alone showed no significant change in CD83 expression (data not shown). We therefore conclude that cichoric acid is not the key component Fig. 4 . High-performance liquid chromatogram and candidate index compounds of the 70% ethanolic extracts from flower, stem plus leaf, and root tissues of E. purpurea. Index compounds 1 and 2 were determined to be cichoric acid and rutin, respectively. phytocompounds that contributes to the modulatory effect on the expression of CD83 in DCs. Augmentation/activation of gene expression by the [R] extract and inhibition by the [S+L] extract for DC maturation might be conferred by different metabolite constituents in these two different plant tissue extracts. In our study we observed that the [R] extract contained a much higher content of alkylamides (3.01% in dry weight) than the [S+L] extract (0.10% in dry weight), suggesting that the observed modulatory effects of root extracts on dendritic cells might be partly contributed by alkylamide compounds. Echinacea alkylamides have been reported to modulate TNFα expression in human monocytes/macrophages via the cannabinoid receptor CB2, and a number of important signaling molecules, such as cAMP, JNK, p38/MAPK kinases, ATF-2/CREB-a, and NF-κB, are involved [18] . We are now investigating whether Echinacea alkylamides could also exhibit modulatory effects on dendritic cell differentiation and associated functions.
Taken together, our results show that E. purpurea plants may confer stimulatory as well as inhibitory effects on specific biological activities of an important human immune cell system, DCs. Further fractionation of such stimulatory or inhibitory bioactivity of phytocompounds from E. purpurea may lead to identification of a lead phytocompound(s) or enriched subfraction as therapeutic or adjuvant therapy for DC-mediated vaccination or immunization, with an ex vivo cell-based assembly system [9] . Furthermore, the use of crude extracts or purified phytocompounds for specific, cell-and/or genebased immune-regulatory activity studies, as reported here, can provide a novel strategy for systematic research into immune cell responsiveness to phytocompounds. Our data demonstrate that the focused "minichip" approach may be useful for efficient cross-talk evaluation of the relative gene expression patterns in DCs as a response to treatment with specific medicinal plant extracts and phytocompounds. Experimental results obtained from such studies, as reported here, could provide baseline, normalizable, and specific information on the future application of traditional medicinal herbs or the derived phytocompounds as immune-modulatory therapeutics.
Materials and methods
Plant materials and plant extract preparations and fractionations
Fresh E. purpurea plants in the flowering stage were obtained from a reputable organic farm in Puli, Taiwan. Plant specimens were deposited as Ep00l at the Agricultural Biotechnology Research Center, Academia Sinica (Taiwan, ROC). Fresh plant samples were separated into four parts/groups: whole plant, stem plus leaf, root, and flower, and each plant material preparation was extracted at room temperature with 70% aqueous ethanol for 30 to 40 days, to follow the traditional Chinese medicine way. The final 70% ethanol-soluble fraction was collected by centrifugation at 24,000g for 20 min at 4°C and then evaporated to dryness by Rotavapor. 
Preparation of human DCs and growth in primary cultures
Human peripheral blood mononuclear cells (PBMCs) were isolated from blood samples drawn from normal healthy volunteers at the Red Cross Blood Center in Taipei City, Taiwan. Human monocytes were isolated and enriched by a three-step protocol. Briefly, PBMCs were isolated by centrifugation with a Ficoll-Metrizoate density gradient (d = 1.077; Amersham Pharmacia Biotech, Uppsala, Sweden), and collected cells were resuspended and washed twice with 1× phosphate buffered saline (PBS). PBMCs were further enriched by spinning in Percoll gradient solution (isosmotic solution: PBS/citrate, 11/9) at 1400 rpm for 30 min. The mononuclear cell layer was collected and washed twice with 1× PBS buffer, and the enriched PBMC samples were incubated with anti-CD14 monoclonal antibody bound to microbeads and finally purified by passing through a magnetic cell separation system (Miltenyi Biotec, Germany) with column type LR. The purity of the PBMCs reached more than 95% CD14 + as high-quality DC precursor cells. DCs were then prepared by culturing at 37°C in 5% CO 2 for 7 days in AIM-V cell growth medium in the presence of human GM-CSF (1000 U/ml; Peprotaq) and IL-4 (500 U/ml; Peprotaq). Cytokines were replenished every 3 days. DCs showed high levels of the MHC class I and the CD86 markers on flow cytometry analysis [19, 20] . Purity of DCs from different batches of preparations was routinely obtained at a range of 92 to 94% homogeneity.
Treatment of DCs with E. purpurea tissue extracts
Dried plant extracts from different plant organs/tissues of E. purpurea were dissolved in 100% pure and endotoxin-free dimethyl sulfoxide (DMSO). The working concentrations of each extract sample were prepared by serial dilutions to 1, 10, 100, and 500 μg/ml, the final DMSO concentration reached 0.1% in each DC culture. Individual E. purpurea extract samples were tested for their ex vivo effect on immature DCs in 1 ml AIM-V growth medium (Gibco BRL, Rockville, MD, USA), in the presence of 0.1% DMSO. LPS from Escherichia coli (serotype 055:B5) was purchased from Sigma (St. Louis, MO, USA) and used as a positive control in the assays [21] . An aliquot of a 0.1% DMSO solution in medium only was used as a vehicle (negative) control.
Flow cytometry analysis
Immature DCs were treated with the four E. purpurea plant extracts for 24 h and then harvested and analyzed by double-color immunofluorescence staining. Monoclonal antibodies against HLA-DR-FITC (Immunotech, Fullerton, CA, USA) were used to stain the MHC class I molecules. Antibodies against CD14-PE, CD32-PE, CD83-FITC (Immunotech, Fullerton, CA, USA), and CD86-FITC (Pharmingen, San Diego, CA, USA) were used for cell flow cytometry analysis [22] . After cell samples were incubated with test antibody at 4°C for 30 min, cells were washed twice with PBS and fixed with 1% paraformaldehyde. Dead cells and possibly contaminating lymphocytes were gated out on the basis of their size and concentration. Analysis involved use of a Coulter EPICS XL flow cytometer (Beckman-Coulter, NC, USA).
Cell viability assay
Cell viability was assayed by use of the MTT colorimetric dye reduction method [23] [24] [25] . MTT solution was obtained from Sigma. A 5-mg/ml stock solution in PBS was sterilized by filtration and stocked at −20°C in a darkened bottle. The testing extracts or phytocompounds were serially diluted (1, 10, 100, and 500 μg/ml) with the basal cell culture medium in 96-well microculture plates (50 μl/well), and 4 × 10 5 immature DCs/ml in the basal medium (50 μl) were added to each microwell. All test samples were performed in triplicate per individual treatment, and test DCs were cultured for 24 h, at 37°C, in a 5% CO 2 incubator. Cells in suspension were removed and washed once with 1× PBS solution, 10 μl of the MTT solution was added to each well, and cells were cultured for another 4 h at 37°C. Aliquots of 100 μl of 100% DMSO were added to each well by gentle mixing on a plate mixer for 10 min at room temperature. The absorbance at 570 nm (OD 570 ) of each well was measured by use of a multiwell scanning spectrophotometer. The viable DCs were calculated according to the following formula: viable cell number (%) = OD 570 (extracttreated DCs)/OD 570 (vehicle-treated control cells) ×100.
RNA isolation
Immature DCs were isolated from the PBMC preparations. High-purity (>90%) human monocytes in suspension (1 × 10 7 cells) were aliquoted into each well of the 10-cm plastic tissue culture plates and incubated at 37°C in 5% CO 2 for 7 days. Cytokine-containing media were replenished on the third day in culture. After 7 days in primary culture, virtually all (≥96%) monocytes had differentiated into immature DCs. At this time, conditioned culture media were removed and the immature DCs were cocultured with test herbal extracts at 100 μg/ml or as specified for 4 to 16 h. The 70% ethanolic extracts from Echinacea [R] and [S+L] were used in these experiments. RNA samples were prepared from monolayer cells lysed directly in a culture dish with the use of Trizol reagent (1 × 10 7 cells per milliliter of Trizol reagent) [26] . Briefly, DCs were collected by stripping the cells using a rubber policeman, lysed with Trizol reagent, and then extracted with chloroform. The top aqueous phase was collected by centrifugation at 4°C, 14,000 rpm for 15 min, and RNA was precipitated from solution by adding an equal volume of isopropanol. RNA pellets were washed twice with 75% ethanol/DEPC and dissolved in DEPCtreated water. The concentration and quality of the RNA samples were analyzed by the relative absorbance of OD 260 /OD 280 and the banding pattern in agarose gel electrophoresis [27] .
Oligonucleotide probe designs
With our design of a focused, function-targeted DNA microarray in a minichip arrangement, we selected 225 genes involved in chemotaxis (chemokine and chemokine receptor), antigen processing (receptor for phagocytosis, molecules for cell adhesion or associated with DC maturation, homing molecules or molecules for antigen presentation, and other molecules associated with immune cell interactions), signaling in DCs (TNF superfamily molecules, receptor-ligand-associated protein kinases, and phosphatase), apoptosis, other immune-related functions (cytokines, cytokine receptors, molecules expressed on T cell or myeloid progenitor cells), and housekeeping. Oligomers were designed with a size of approximately 50 nucleotides to represent these genes specifically by the U-GET program developed by UVision Biotech, Inc. (Taipei, Taiwan, ROC).
Reverse transcription and first-strand cDNA labeling with amino allyl-dUTP (AA-dUTP)
A total RNA sample (20 μg) was mixed with 3 μl of Oligo(dT) primer (Amersham Pharmacia Biotech, UK) and heated at 70°C for 5 min and then cooled for 10 min at room temperature. The reaction mixture (in a total volume of 20 μl) contained 4 μl of 5× first-strand buffer, 2 μl of 0.1 M DTT, 1 μl of a 20× nucleotide mixture, 1 μl AA-dUTP, and 1 μl of reverse transcriptase Superscript II (Amersham; CyScribe Post-Labeling Kit). Reverse-transcription reaction was performed at 42°C for 1.5 h and terminated by the addition of 2 μl 2.5 M NaOH, followed by incubation at 37°C for 15 min. As a final step, 10 μl of 2 M Hepes was added to neutralize the reaction. A Microcon purification kit (Millipore, YM 30) was then used to clean up the synthesized cDNA product. The cDNA pellet was then speed-vacuum-dried and resuspended in 15 μl water [28] .
Labeling of amino allyl-modified cDNA with CyDye
One aliquot of CyDye (Cy3 or Cy5) was resuspended into 15 μl of fresh 0.1 M sodium bicarbonate (pH 9.0) immediately prior to use in a labeling reaction. The Cy3 dye was added to a tube containing amino allyl-modified cDNA as the "control" (untreated) sample and the Cy5 to the test (treated) sample. Samples were mixed by stirring and incubated at room temperature in the dark for 1 h, and then 15 μl of 4 M hydroxylamine was added to each coupling reaction, mixed well, and incubated at room temperature in the dark for another 15 min. Finally, the CyDye-labeled cDNAs were purified with the use of a DNA purification kit from Qiagen (Cologne, Germany). The allyl-modified cDNA pellet was then speed-vacuum-dried and resuspended in 5 μl water.
Hybridization and signal detection of oligo-DNA microarrays
The oligo-DNA probe was prepared in a fresh hybridization solution consisting of 30% formamide, 5× SSC, 0.1% SDS, and 0.1 mg/ml of a nucleic acid blocker (e.g., human Cot 1 DNA) and then mixed with RNA sample. The probe and RNA sample solutions were incubated at 95°C for 5 min, centrifuged for 2 min to collect condensation, and cooled to room temperature for 20 min. The sample solution was then loaded onto the surface of the printed side of the array slides and the coverslip was carefully placed on top of the arrays to avoid creating bubbles. DNA arrays in a hybridization chamber (Corning, Cat. No. 2551) were then placed in a 42°C water bath for 16 h. After incubation, the arrays were placed in 2× SSC, 0.1% SDS solution at 42°C, washed for 5 min, and then changed to another wash buffer containing 0.1× SSC and 0.1% SDS at room temperature for 5 min; the wash was repeated once. In the final step, the arrays were placed in 0.1× SSC wash buffer at room temperature for 1 min and the wash was repeated four times. Arrays were dried by centrifugation (800 rpm, 10 min) and analyzed for signals emitted from each spot with digital imaging software (Genepix 4.0). Quantification of index compounds (1 and 2) in the chromatogram of known concentrations of the three tissue extracts was calculated on the basis of a standard calibration curve of the individual index compounds. The metabolite profiles and the relative content of the two index compounds were routinely used for quality control of the specific test tissue extracts [29] . The total content of alkylamides in the [F], [R] , and [S+L] extracts of E. purpurea was also quantitatively determined. We observed that nine major alkylamide compounds could be readily detected in our RP-HPLC analyses. The nine alkylamides in E. purpurea extracts were then characterized and quantified. The total amount of alkylamides present in the specific tissue extracts was calculated by the summation of the contents of the nine alkylamides detected in the chromatogram of a known concentration of a specific tissue extract, using a standard calibration curve of the alkylamides. The alkylamide concentrations in the [F], [S+L] , and [R] extracts of E. purpurea were determined to be approximately 0.39, 0.10, and 3.01% (in dry weight of test plant extracts), respectively.
HPLC analysis of E. purpurea extracts
